Compile Data Set for Download or QSAR
Report error Found 636 Enz. Inhib. hit(s) with all data for entry = 11103
TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590629(US11560381, Compound D428)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590628(US11560381, Compound D427)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590627(US11560381, Compound D426)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590634(US11560381, Compound D433)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590632(US11560381, Compound D431)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590631(US11560381, Compound D430)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590637(US11560381, Compound D436)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590635(US11560381, Compound D434)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590642(US11560381, Compound D441)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590641(US11560381, Compound D440)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590640(US11560381, Compound D439)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590639(US11560381, Compound D438)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590614(US11560381, Compound D413)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590613(US11560381, Compound D412)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590612(US11560381, Compound D411)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590611(US11560381, Compound D410)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590618(US11560381, Compound D417)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590617(US11560381, Compound D416)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590616(US11560381, Compound D415)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590615(US11560381, Compound D414)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590622(US11560381, Compound D421)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590621(US11560381, Compound D420)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590620(US11560381, Compound D419)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590619(US11560381, Compound D418)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590626(US11560381, Compound D425)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590625(US11560381, Compound D424)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590624(US11560381, Compound D423)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590623(US11560381, Compound D422)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590661(US11560381, Compound D460)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590660(US11560381, Compound D459)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590659(US11560381, Compound D458)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590666(US11560381, Compound D465)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590664(US11560381, Compound D463)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590663(US11560381, Compound D462)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590670(US11560381, Compound D471)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590667(US11560381, Compound D466)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590645(US11560381, Compound D444)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590644(US11560381, Compound D443)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590643(US11560381, Compound D442)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590649(US11560381, Compound D448)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590654(US11560381, Compound D453)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590653(US11560381, Compound D452)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590651(US11560381, Compound D450)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590658(US11560381, Compound D457)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590657(US11560381, Compound D456)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590656(US11560381, Compound D455)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590655(US11560381, Compound D454)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetBromodomain-containing protein 9 [133-239](Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565268(US11414416, Compound D9 | US11560381, Compound D9)
Affinity DataIC50: 10nMAssay Description:Procedure: His-Flag-BRD9 (P133-K239; Swiss Prot Q9H8M2; SEQ ID NO:1 mgsshhhhhhenlyfq/gdykddddkgslevlfqg/PAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMII...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetBromodomain-containing protein 9 [133-239](Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565267(US11414416, Compound D8 | US11560381, Compound D8)
Affinity DataIC50: 10nMAssay Description:Procedure: His-Flag-BRD9 (P133-K239; Swiss Prot Q9H8M2; SEQ ID NO:1 mgsshhhhhhenlyfq/gdykddddkgslevlfqg/PAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMII...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetBromodomain-containing protein 9 [133-239](Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565274(US11414416, Compound D15 | US11560381, Compound D1...)
Affinity DataIC50: 10nMAssay Description:Procedure: His-Flag-BRD9 (P133-K239; Swiss Prot Q9H8M2; SEQ ID NO:1 mgsshhhhhhenlyfq/gdykddddkgslevlfqg/PAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMII...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

Displayed 1 to 50 (of 636 total ) | Next | Last >>
Jump to: